Upcoming Conferences, Financial Results, New Products, and Awareness Campaigns - Analyst Notes on Align Technology, LabCorp, Insulet, CareFusion, and DexCom
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, March 11, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Align Technology, Inc. (NASDAQ:ALGN), Laboratory Corp. of America Holdings (NYSE:LH), Insulet Corporation (NASDAQ:PODD), CareFusion Corporation (NYSE:CFN), and DexCom, Inc. (NASDAQ:DXCM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Align Technology, Inc. Analyst Notes
On March 6, 2014, Align Technology, Inc. (Align Technology) announced its participation at the upcoming 26th Annual Roth Conference, wherein President and CEO, Thomas M. Prescott, and David White, CFO, will address participants. The Company informed that the presentation is scheduled on March 11, 2014 from 9:30 a.m. to 10:00 a.m. PT at Dana Point, California. Align Technology added that a live webcast of the presentation can be accessed via the Company website, where an archived replay will also be available for approximately three months. The full analyst notes on Align Technology, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03112014/ALGN/report.pdf
Laboratory Corp. of America Holdings Analyst Notes
On March 4, 2014, Laboratory Corp. of America Holdings (LabCorp) announced that Chairman and CEO, David P. King, is scheduled to speak at the Barclays Capital 2014 Global Healthcare Conference in Miami Beach, Florida. The Company stated that its presentation will take place on Tuesday, March 11, 2014 at 10:45 a.m. ET. LabCorp added that a live audio webcast of the presentation, as well as its replay, will be available via its website. The full analyst notes on Laboratory Corp. of America Holdings are available to download free of charge at:
http://www.AnalystsReview.com/03112014/LH/report.pdf
Insulet Corporation Analyst Notes
On February 27, 2014, Insulet Corporation (Insulet) reported its Q4 2013 and full-year 2013 results. Insulet posted revenues of $68.5 million, up 18.5% YoY for the quarter; while annual revenues were up 16.9% to $247.1 million. For the quarter, the Company's net loss stood at $2.5 million or $0.04 per diluted share, compared to net loss of $10.2 million or $0.21 per diluted share in Q4 2012. Full-year 2013 net loss was c.$45 million or $0.83 per diluted share, compared to $51.9 or $1.08 per diluted share in full year 2012.Duane DeSisto, President and CEO of Insulet, commented, "2013 was one of the most exciting years in Insulet's history, and I am proud of all that our team accomplished. We launched the smaller, lighter OmniPod, transitioned all of our OmniPod customers to the new product in less than six months and established manufacturing operations capable of producing nearly one million pods per month. " Insulet stated that for Q1 2014, revenue is expected to be in the range of $67 million to $71 million; and to be in the range of $295 million to $315 million for full year 2014.The full analyst notes on Insulet Corporation are available to download free of charge at:
http://www.AnalystsReview.com/03112014/PODD/report.pdf
CareFusion Corporation Analyst Notes
On March 6, 2014, CareFusion Corporation (CareFusion) announced the global launch of a new line of electrosurgical instruments under the V. Mueller® brand. According to CareFusion, the new V. Mueller line of bipolar electrosurgical instruments will consist of both forceps and scissors with approximately 200 options including non-stick, titanium and irrigating options to meet the specific requirements of surgeons. The Company added that the new scissors also feature a single-point connection to the electrical source, reducing the number of wires attached to the handles to improve maneuverability and ease-of-use. Commenting on the launch, Andreas Lex, Vice President and General Manager for V. Mueller and Snowden-Pencer® surgical instruments for CareFusion, stated, "Expanding our electrosurgical line to include enhanced bipolar options is good for both our customers and their patients. V. Mueller has been a trusted name in surgical instruments for decades, and the new line reinforces our commitment to innovation for today's modern surgeries." The full analyst notes on CareFusion Corporation are available to download free of charge at:
http://www.AnalystsReview.com/03112014/CFN/report.pdf
DexCom, Inc. Analyst Notes
On March 5, 2014, DexCom, Inc. (DexCom) announced its support for NASCAR driver Ryan Reed and the American Diabetes Association's Drive to Stop Diabetes℠ national diabetes awareness initiative.The Company stated that under the campaign, Dexcom will support Ryan Reed and the Association's Drive to Stop Diabetes to build awareness about the importance of daily monitoring and tracking of glucose trends in the management of diabetes. Ryan Reed, NASCAR driver, commented, "At the age of 17 I received the life-changing news that I had type 1 diabetes and was told I would never race again. I refused to give up my racing dream and have since learned to manage my disease through a balanced diet, exercise and understanding my blood glucose. My Dexcom G4® Platinum has been my safety belt in tracking my glucose levels on major race days and in everyday life and for that, I am happy to be working with them." The Company stated that the Dexcom G4® PLATINUM tracks glucose levels continuously and uses wireless technology to enable users to view their glucose levels on demand. The full analyst notes on DexCom, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03112014/DXCM/report.pdf
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
Share this article